abstract: Infertility is a growing concern in modern society, with 30% of cases being due to male factors, namely reduced sperm concentration, decreased motility and abnormal morphology. Sperm cells are highly compartmentalized, almost devoid of transcription and translation consequently processes such as protein phosphorylation provide a key general mechanism for regulating vital cellular functions, more so than for undifferentiated cells. Reversible protein phosphorylation is the principal mechanism regulating most physiological processes in eukaryotic cells. To date, hundreds of protein kinases have been identified, but significantly fewer phosphatases (PPs) are responsible for counteracting their action. This discrepancy can be explained in part by the mechanism used to control phosphatase activity, which is based on regulatory interacting proteins. This is particularly true for PP1, a major serine/threonine-PP, for which .200 interactors (PP1 interacting proteins-PIPs) have been indentified that control its activity, subcellular location and substrate specificity. For PP1, several isoforms have been described, among them PP1g2, a testis/sperm-enriched PP1 isoform. Recent findings support our hypothesis that PP1g2 is involved in the regulation of sperm motility. This review summarizes the known sperm-specific PP1-PIPs, involved in the acquisition of mammalian sperm motility. The complexes that PP1 routinely forms with different proteins are addressed and the role of PP1/A-kinase anchoring protein complexes in sperm motility is considered. Furthermore, the potential relevance of targeting PP1-PIPs complexes to infertility diagnostics and therapeutics as well as to male contraception is also discussed.
Introduction
Reversible phosphorylation of structural and regulatory proteins is a major intracellular control mechanism in eukaryotes. It controls almost all cellular functions-for example, metabolism, signal transduction, cell division and memory. The phosphorylation state of a protein is a dynamic process involving both protein kinases and protein phosphatases (PPs). Unlike protein kinases that all belong to a single gene family, PPs are divided into several distinct and unrelated protein/gene families. The Tyr-specific PP family, as well as including the Tyr-specific PPs, also comprises the so-called dual specificity PPs (capable of dephosphorylating Ser, Thr and Tyr residues). Within the Ser/Thr-specific PPs (STPPs), three distinct gene families have been described: the PPM (Mg 2+ or Mn 2+ dependent PPs), the FCP [transcription factor (TF)IIF-associating C-terminal domain phosphatases] and the PPPs (phosphoprotein phosphatases). The PPM family comprises the Mg 2+ -dependent PPs, such as pyruvate dehydrogenase, PP2C and relatives (Barford et al., 1998) . The FCP family comprises FCP1 and SCPs 1-3 PPs (Yeo et al., 2003; Gallego and Virshup, 2005) . The PPP family includes PP1, PP2A/PP4/PP6, PP2B, PP5 and PP7 ( Table I ) gene subfamilies that share high homology in the catalytic domains but differ in the N-and C-terminal domains (Cohen, 1997; Barford et al., 1998; Honkanen and Golden, 2002) . Several PPP family members have been shown to be expressed in cells from testis and/or sperm, suggesting an important function in these cellular types (Table I) . Besides these intracellular PPs involved in signal transduction, there are also unrelated non-specific alkaline and acidic PPs that are usually found either in specialized intracellular compartments † Deceased on 2 March 2010.
or in the extracellular milieu (Sood and Majid, 1987) . The role of Tyrspecific PPs in mammalian sperm motility will not be addressed as it goes beyond the scope of this review; literature on the topic is available (e.g. Gonzalez-Fernandez et al., 2009) . The sequencing of entire genomes has revealed that 3% of all eukaryotic genes encode protein kinases or PPs (Plowman et al., 1999) . Surprisingly, there appear to be 2-5 times fewer PPs than protein kinases. This imbalance is even more pronounced when the analysis is limited to Ser/Thr-PPs and kinases, particularly in vertebrates. The human genome, for instance, encodes 20 times fewer Ser/ Thr-PPs than Ser/Thr-kinases. Thus, it is often concluded that whereas the diversity of the Ser/Thr-protein kinases has kept pace with the increasing complexity of evolving organisms, the Ser/Thr-PPs apparently have not. However, in the past two decades, it has become evident that the diversity of Ser/Thr-PPs is achieved not only by the evolution of new catalytic subunits, but also by the ability of a single catalytic subunit to interact with multiple regulatory subunits.
Protein phosphatase 1 (PP1) is a major Ser/Thr-PP involved in a wide range of cellular processes and exists in the cell as an oligomeric complex. The catalytic subunit binds a spectrum of interacting proteins, PP1 interacting proteins (PIPs), that modulate both its intracellular localization and substrate specificity (Cohen, 2002; Ceulemans and Bollen, 2004; Virshup and Shenolikar, 2009) . A variety of approaches have identified .200 PIPs and many more remain unknown considering the number of phosphatases and phosphoprotein substrates encoded for by the human genome (Cohen, 2004; Johnson and Hunter, 2005) .
In addition to the signalling diversity provided by targeting subunits, PP1 is also expressed in mammalian cells as three closely related isoforms (a, b and g), which are encoded by separate genes. These isoforms are .90% identical in amino acid sequence, with minor differences primarily at their N-and C-terminus (Cohen, 2002) . Although most biochemical studies have not directly addressed the significance of the different isoforms, it is now well established that they have distinct subcellular localizations as well as distinct tissue specificity (Andreassen et al., 1998; Trinkle-Mulcahy et al., 2001; Fardilha et al., 2008) . This implies differences in their specificity of interaction with particular PIPs, which may in turn exhibit subcellular compartmentalization or tissue-specific enrichment. For example, the neuronal actin-binding proteins, neurabin I and II, target PP1 to the actin-rich post-synaptic density, where it regulates the dendritic spine morphogenesis and maturation. The former preferentially bind the PP1g1 isoform over the other two isoforms, PP1a and PP1b (Allen et al., 1997; Terry-Lorenzo et al., 2002a,b; Terry-Lorenzo et al., 2005) .
Splicing of the PP1g gene originates another isoform, termed PP1g2, which is enriched in testis and virtually exclusive to sperm Shima et al., 1993a,b; da Cruz e Silva et al., 1995; Smith et al., 1996; Fardilha et al., 2008) (Table I ). In testis, PP1g2 is localized in the cytoplasm of secondary spermatocytes and round spermatids, as well as elongating spermatids and testicular and epididymal spermatozoa, while PP1g1 expression is observed in interstitial cells and PP1a in spermatogonia, pachytene spermatocytes and interstitial cells (Chakrabarti et al., 2007) . PP1g gene null male mice are infertile due to impaired spermatogenesis, leading to the absence of epididymal spermatozoa . Although PP1a expression was increased and its localization altered, it could not substitute for PP1g, further suggesting a specific role for PP1g2 in 
PP1a
Ubiquitous; more predominantly in brain and lung (Shima et al., 1993a,b) Yes (Shima et al., 1993a,b) Y e s ( Suzuki et al., 2010; Fardilha, unpublished data) 
PP1b
Ubiquitous; more predominantly in brain, intestine and lung (Shima et al., 1993a,b) Yes (Shima et al., 1993a,b) N o PP1g 1 Ubiquitous; more predominantly in brain (Shima et al., 1993a,b) Yes (Shima et al., 1993a,b) N o PP1g 2 Yes, low abundance (Strack et al., 1999) Y e s Sasaki et al., 1990; Shima et al., 1993a,b) Yes (Shima et al., 1993a,b; Smith et al., 1996; Vijayaraghavan et al., 1996) PP2A Ubiquitous; more predominantly in brain (Khew-Goodall and Hemmings, 1988) Yes (Kloeker et al., 2003) Y e s PP2B Ubiquitous; more predominantly in brain (Wallace et al., 1980) Yes (Ueki et al., 1992; Chang et al., 1994) Yes (Tash et al., 1988) PP4 Ubiquitous; more predominantly lung, liver and kidney (Hu et al., 2001) sperm differentiation and morphogenesis (Chakrabarti et al., 2007) . Several studies have demonstrated that PP1g2 is important in regulating sperm motility (Smith et al., , 1999 Huang et al., 2002; Mishra et al., 2003) . In sperm, PP1g2 is present along the entire flagellum including the middle-piece, consistent with a role in sperm motility, but it is also found in the posterior and equatorial regions of the head, suggesting a role in the acrosome reaction (Huang et al., 2002) . Furthermore, Visconti et al. (1997) have recently shown that inhibition of PPs induces capacitation-associated signalling (Krapf et al., 2010) . Immotile spermatozoa possess higher activity levels of PP1g2 compared with motile spermatozoa. Inhibition of PP activity by okadaic acid and calyculin A initiates motility in caput epididymal sperm without requirement for a change in cyclic AMP (cAMP) levels Vijayaraghavan et al., 1996) . Additionally some testis/sperm-specific PIPs have been identifiedfor example, the spermatogenic zip protein 1 (Szp1), a member of the basic helix-loop-helix family of transcription factors, which binds to PP1g2 in mouse testis (Hrabchak and Varmuza, 2004) . Overexpression of Szp1 and loss of PP1g in the testis show similar phenotypes, such as spermatogenic arrest and germ cell apoptosis (Hsu et al., 2004) . Another example is endophilin B1t, this testis-enriched isoform of endophilin B1a was shown to bind PP1g2 but did not interact with a mutant form of PP1g2, lacking the specific C-terminus, nor with PP1a (Hrabchak et al., 2007) . Moreover, the somatic isoform did not interact with any of the PP1 isoforms and the characteristic punctuate expression pattern of endophilin, in testis, was absent in PP1g null mice. Finally, endophilin B1t was able to inhibit recombinant PP1g2 activity (Hrabchak et al., 2007) . Other proteins have also been implicated in the regulation of PP1g2 in testis/sperm either by inducing (14-3-3) or inhibiting [hsp90 and suppressor of dism2-mutation protein (sds22)] PP1g2 activity during sperm maturation (Shima et al., 1993a,b; Jurisicova et al., 1999; Huang et al., 2002; Mishra et al., 2003; Hrabchak and Varmuza, 2004; Huang et al., , 2005 . This review will describe the signalling transduction mechanism relying on PP1g2 and its binding partners for the acquisition of sperm motility. In particular, a detailed discussion on A-kinase anchoring proteins (AKAPs), as PP1 binding partners, will be addressed. A new concept of male infertility therapy or male contraception strategy based on the modulation of PP1g2/PIPs complexes will also be considered.
Mechanisms involving PP1g2 in the acquisition of sperm motility
Several studies have demonstrated the involvement of cyclic nucleotides, bicarbonate, cholesterol and protein phosphorylation in the acquisition of progressive motility, capacitation, hyperactivation of motility, directed motility or induction of the acrosome reaction (Garbers and Kopf, 1980; Smith et al., 1996; Vijayaraghavan et al., 1996 Vijayaraghavan et al., , 1997 Cross, 1998; Visconti and Kopf, 1998; Smith et al., 1999; Huang et al., 2002; Mishra et al., 2003) . Calcium ions are also primary determinants of sperm cell behaviour, being absolutely required for the processes described above (Yoshida et al., 2008) . Immunostaining studies and transcript analysis revealed that spermatozoa possess several calcium channels. Calcium signalling in sperm will not be addressed in this review.
Given that sperm are terminally differentiated cells essentially devoid of transcriptional and translational activity, they are an ideal model system to study the regulation of PP1 in relation to motility and metabolism. Of note, several lines of evidence have demonstrated that PPs are direct players in the acquisition of sperm movement. Indeed, PP1 inhibition of immotile caput sperm with specific inhibitors results in them acquiring motility. Intriguingly, these effects are completely independent of calcium .
The PP1-driven endogenous regulation of protein phosphorylation and sperm motility could represent an important mechanism for physiological regulation of a cell that encounters dramatically different environments, as it journeys through the seminiferous tubules and the female reproductive tract. Previous results Vijayaraghavan et al., 1996) provide strong support for a novel unifying hypothesis, based on the observation that PP1 is present in sperm and that pharmacological modulation of its activity profoundly affects sperm motility. In other cell types, PP1 has been implicated in the control of very diverse processes such as cellular metabolism, muscle contraction, mitosis, neurotransmitter release, etc. (Cohen, 2002; Ceulemans and Bollen, 2004; da Cruz e Silva et al., 2004) . Regulation of these processes involves complex intracellular pathways, initiated by activation of distinct receptors and second messenger systems (Greengard et al., 1999) . However, the precise role played by PPs and their regulation have only recently started to be elucidated. The available data demonstrate their highly regulatable nature, contrary to previous opinions. One particularly interesting mechanism for controlling PP1 activity involves its inhibition by heat-stable PP inhibitors I1, and I2, phosphoproteins whose state of phosphorylation controls their inhibitory activity. I1 is phosphorylated by cAMPdependent protein kinase and dephosphorylated by the phosphatase calcineurin (PP2B). Thus, PP1 is involved in the cross-talk between the intracellular messengers calcium and cAMP (Greengard et al., 1999) . The diversity of PP1 function is achieved by its capacity to form functionally distinct multimeric complexes.
The complex PP1g2/I2-L/GSK-3
Inhibitor-2 (I2) is capable of inhibiting the catalytic subunit of PP1 leading to the production of a stable PP1-I2 complex. Glycogensynthase kinase (GSK)-3 phosphorylates I2 in the PP1-I2 complex, relieving the inhibition and producing active PP1 (Fig. 1 ). This biochemical pathway is likely to be operative in mammalian sperm since preliminary studies have identified an I2-like activity and also the presence of GSK-3 in mammalian sperm. Immotile bovine caput epididymal sperm contains 2-fold higher levels of PP activity, identified as being PP1g2, and 6-fold higher GSK-3 activity than do mature motile caudal sperm. Thus, the complex PP1g2/ I2-like is inactive in motile caudal sperm and the phosphatase activity is re-established in immotile sperm by the higher GSK-3 activity Vijayaraghavan et al., 1996) . In addition, the phosphatase inhibitors okadaic acid and calyculin A were able to induce motility in completely immotile bovine caput epididymal sperm and to stimulate the kinetic activity of mature caudal sperm.
In our laboratory, by a yeast two-hybrid screen of a human testis library, a positive clone designated I2-L (I2 Like, NM_206858) was identified (unpublished data). The inactive PP1g2-inhibitor complex thus formed cannot be activated by GSK-3 phosphorylation.
Apparently, I2-L represents a constitutive inhibitor of PP1 that is independent of GSK-3 phosphorylation. One hypothesis might be that I2-L is only present in caudal motile sperm, leading to constitutive inactivation of PP1g2. Alternatively I2-L may be bound to a protein that keeps it from binding PP1g2 in immotile caput sperm, paralleling what happens with sds22. The protein complex PP1g2/I2(I2-L)/ GSK-3 may explain the observed unidirectional acquisition of sperm motility along the epididymal transit (Fig. 1) . Our hypothesis is that along the epididymis, I2 concentration decreases while I2-L increases leading to a reduction in PP1 activity from the caput to the caudal portion of the epididymis. This would be a highly physiological relevant explanation for the unidirectional acquisition of sperm motility.
The complex PP1g2/I3 (PPP1R11)
Inhibitor-3 (I3) is a potent heat-stable PP1 inhibitor (Giffon et al., 1996; Zhang et al., 1998) and is a human homologue of the mouse t-complex expressed protein 5 (Tctex5), being genetically linked to the male sterility phenotypes of impaired sperm tail development and poor sperm motility in t-complex mice (Cebra-Thomas et al., 1991; Pilder et al., 1991 Pilder et al., , 1993 . Tctex5 gene synergistically with Tsga2 gene is a candidate for 'curlicue' phenotype, a chronic, negative bend of both the flagellar middle-piece and principal piece of spermatozoon, and for the 'stop' phenotype that prevents sperm from t-haplotype homozygotes from penetrating zona-free egg (Hui et al., 2006; Han et al., 2007; Pilder et al., 2007) . Tctex5 was shown to be present in sperm protein lysates localizing to nuclei of pachytene spermatocytes, round spermatocytes, cytoplasm of sertoli cells, in testis; cilia, secretion bodies and nuclei of epithelial cells and interstitium smooth muscle cells in the epididymis. In epididymal mouse spermatozoa, Tctex5 is present in the head and principal piece of the tail . These are also the locations where PP1g2 is expressed (Huang et al., 2005) .
I3 is a substrate for caspase-3 and is degraded in vivo during apoptosis induced by actinomycin D in HL60 cells, leading to a re-localization of the PP1 cellular pool (Huang and Lee, 2008) . PP1g2 has an anti-apoptotic effect in testis that might result from its ability to increase I3 stability . In male germ cells PP1g2, I3, sds22 and actin form a multimeric complex in which PP1g2 seems to be inactive . The stability of the Figure 1 Illustrative mechanisms of sperm motility acquisition based on protein phosphatase PP1g2 regulation. PP1g2 is inhibited by I2 that is phosphorylated by GSK-3 releasing active PP1g2 in the caput epididymis. In the caudal epididymis, PP1g2 is bound to I2-L that cannot be phosphorylated by GSK-3. The protein 14-3-3 binds PP1g2 and GSK-3 and also other sperm phosphoproteins in the caudal epididymis. Inhibition of PP1g2 activity or activation of PKA through AKAP anchoring will induce sperm motility. This will induce phosphorylation of various sperm proteins. The signals underlying these events are still unknown. PP1g2 may also be inhibited by phosphorylation in a C-terminal threonine residue by a cdk that still needs to be identified. PP1g2 binding to sds22 inhibits its activity in the caudal epididymis. In the caput epididymis, sds22 is unable to inhibit PP1g2 since it is bound to the protein p17. Also, a multimeric complex has been identified composed by PP1g2, sds22, actin and I3, where PP1g2 was inactive. PKA, protein kinase A; GSK-3, glycogen synthase kinase 3; sds22, suppressor of dism2-mutation protein; PP1, protein phosphatase 1.
PP1 modulates sperm motility complex depended on functional PP1 interaction sites in sds22 and I3, indicating that PP1 mediates the interaction between sds22 and I3, forming a catalytically inactive complex in the cell (Lesage et al., 2007) . The function of this complex in sperm motility, if any, needs to be further exploited (Fig. 1) .
The complex PP1g2/sds22 (PPP1R7)
A yeast sds22 homologue, PPP1R7, was identified in sperm (Mishra et al., 2003) , and inhibits the PP1 catalytic subunit in rat liver nuclei (Dinischiotu et al., 1997) . Consistently, an sds22 homologue was also identified in rat testis that associates with PP1g2 (Chun et al., 2000) . The expression pattern of rat sds22 matches that of PP1g2, suggesting that its involvement in spermatogenesis relates to the control of PP1g2 activity. Sds22 was identified in motile caudal spermatozoa as a regulator of PP1g2 catalytic activity (Huang et al., 2002) . In contrast, PP1g2 and sds22 do not interact in caput bovine sperm (Mishra et al., 2003) . This study showed that caput sperm sds22 is bound to a 17-kDa protein, suggesting that binding to PP1g2 requires sds22 dissociation from p17 (Fig. 1) . This protein is present in the principal piece of the spermatozoa flagellum and in the head-neck junction, although in somatic cells it is mainly nuclear. Additionally, sds22 has consensus sites for phosphorylation by GSK-3, protein kinase-A (PKA) and calmodulin dependent kinase II, all present in sperm.
The complex PP1g2/14-3-3
PP1g2, as well as other PP1 isoforms, have at the C-terminus a consensus TPPR amino acid sequence containing a threonine residue (T311) that can be phosphorylated by cyclin-dependent kinase 2 (cdk2), reducing its activity (Brautigan, 1995; Kwon et al., 1997; Liu et al., 1999) . The proportion of phosphorylated PP1g2 in caudal sperm is higher than in caput epididymal sperm and is localized to the posterior region of the sperm head, the equatorial region, implicated in sperm-egg binding, and in the principal piece of the sperm tail . Interestingly, cdk2 knockout mice are viable but male and female are sterile (Berthet et al., 2003; Ortega et al., 2003) . Vijayaraghavan et al. proposed that regulation of PP1g2 activity by cdk2 phosphorylation may be a mechanism for developing sperm motility. This might be achieved through binding of PP1g2 to the bridging molecule 14-3-3. In sperm 14-3-3 binds PP1g2 . The 14-3-3 protein is highly conserved among eukaryotic cells and acts as an adaptor protein in cellular signalling and metabolism. More than 100 binding partners have been identified, using affinity chromatography coupled with proteomic analysis (Milne et al., 2002; Jin et al., 2004; Meek et al., 2004; Pozuelo Rubio et al., 2004 ). 14-3-3 and its binding partners are regulators of proteinprotein interactions during spermatogenesis (Sun et al., 2009) . It is consistent that 14-3-3 appears to regulate diverse cellular events such as cell cycle, apoptosis, protein trafficking, cytoskeleton rearrangements and metabolism (Gardino et al., 2006) . The study of 14-3-3 interactome in bull sperm identified many proteins involved in different cellular events, from acrosome reaction to metabolism (Puri et al., 2008a,b) . In particular, GSK-3 was found to bind 14-3-3 (Puri et al., 2008a,b) (Fig. 1) . As already stated, changes in tyrosine and serine phosphorylation of GSK-3 occur in parallel with motility stimulation in sperm (Somanath et al., 2004) . The exact functions of 14-3-3, through binding to sperm phosphoproteins, are the subject of extensive research.
The complex PP1g2/AKAP/PKA
The cAMP-dependent PKA and PP1 are broad specificity signalling enzymes with opposing actions that catalyse changes in the phosphorylation state of cellular proteins. PKA is a ubiquitous, multifunctional enzyme involved in the regulation of several cellular events. PKA holoenzyme consists of four subunits: two catalytic and two regulatory (RI and RII). Subcellular targeting to the vicinity of preferred substrates is a means of restricting the specificity of these enzymes (Hubbard and Cohen, 1993; Faux and Scott, 1996) . Several PP1 targeting subunits direct PP1 to specific locations (Egloff et al., 1997; Cohen, 2002; Ceulemans and Bollen, 2004; Hendrickx et al., 2009; Fardilha et al., 2010) , while compartmentalization of PKA is mediated through association of its regulatory subunits with AKAPs (Faux and Scott, 1996) . To date, over 40 AKAPs have been identified, targeting PKA to the plasma membrane, cytoskeleton, endoplasmic reticulum, Golgi, mitochondria and nuclear matrix Schillace et al., 2001; Logue and Scott, 2010; Scott and Santana, 2010) . This high level of molecular organization ensures selectivity in cAMP-responses.
Several anchoring proteins have been identified that can simultaneously associate with kinases and phosphatases (Faux and Scott, 1996) . These deserve specific attention as they are important in the tight control of phosphorylation/dephosphorylation mechanisms. In testis and/or sperm, there are three AKAPs that have been shown to be related to PP1g2 (AKAP220, AKAP4 and AKAP3, Table II). AKAP220 binds PKA and PP1, being a competitive inhibitor of PP1 (Schillace et al., 2001) . In testis, AKAP220 associates with PKA, where it may target the kinase to peroxisomes (Lester et al., 1996) . AKAP220 mRNA is expressed at high levels in human testis and in isolated human pachytene spermatocytes and round spermatids (Reinton et al., 2000) . AKAP220 is present in human male germ cells and mature sperm, and like RIIa, it is located in the middle-piece and is probably associated with cytoskeletal structures (Reinton et al., 2000) . The centrosomal AKAP220/PKA complex may regulate spindle formation during meiosis. The middle-piece associated AKAP220 could serve to anchor PKA and/or PP1g2, directly regulating the contractile machinery in the sperm axoneme. Furthermore, it has been shown that disruption of RII interaction with AKAPs, by membrane-permeable peptides, causes the arrest of sperm motility (Vijayaraghavan et al., 1997) .
AKAP82 (AKAP4) cDNA was first isolated from a mouse testis cDNA-expression library, by using an antiserum to fibrous sheaths isolated from mouse sperm (Carrera et al., 1994 (Carrera et al., , 1996 . In a screen of a mouse round spermatid cDNA library, a cDNA was isolated that encoded a protein referred to as fibrous sheath component 1 (FSC1) (Fulcher et al., 1995) . FSC1 and AKAP82 are alternative spliced isoforms of the Akap4 gene, present on the X chromosome of mouse and human (Turner et al., 1998) . Mouse Akap4 expression was only detected in testis and it was determined that transcription is initiated at 20-22 days after birth and the mRNA is present in spermatids but not in pachytene spermatocytes (Carrera et al., 1994; Fulcher et al., 1995) . In RNA from testes extracts of hamster, guinea pig, rabbit, ram, and human, transcripts that hybridized to the mouse Akap4 cDNA were found (Fulcher et al., 1995) . AKAP4 protein was found to be synthesized as a precursor present throughout the principal piece in testicular sperm. A small peptide corresponding to the precursor fragment and a higher molecular weight protein, possibly a phosphorylated form of the precursor, are present in epididymal sperm in low amounts. In mouse sperm, AKAP4 was detected throughout both the longitudinal columns and the semi-circumferential ribs of the fibrous sheath . All these findings correlate with a restricted temporal and spatial expression of the AKAP4 protein, present only in spermatogenetic cells and the predominant protein in the fibrous sheath of the sperm flagellum. Targeted disruption of the Akap4 gene causes absence of sperm motility together with a complete lack of fibrous sheath on the principal piece of mature mice sperm, causing male mice to be infertile (Miki et al., 2002) . In spermatozoa, Akap4 gene knockout mice that lack flagellar movement exhibit a significant change in the activity and phosphorylation of PP1g2 (Huang et al., 2005) . This suggests the involvement of AKAP4 in the regulation of PP1g2 activity in the principal piece of mouse spermatozoa.
AKAP3 was first described as a protein of Mr 120 000 in bovine sperm, known to bind the RII subunit of PKA (Horowitz et al., 1984) , and an RII-binding protein of similar mass was detected in sperm, from mouse (Lin et al., 1995) , human and monkey (Vijayaraghavan et al., 1997) . cDNAs were isolated from mouse, human and bovine testis libraries and transcripts were only found in spermatids. Also, rabbit antiserum to a peptide sequence in the protein, referred to as AKAP110, bound to the principal piece and acrosome of bovine sperm . A protein recognized by sera from infertile men and women was microsequenced and PCR was used to clone the human cDNA (Mandal et al., 1999) . This protein, also referred to as FSP95, undergoes tyrosine phosphorylation during in vitro capacitation of human sperm. Northern blot analysis of RNA from 50 human tissues determined that the transcripts are found only in testis, more specifically in round spermatids. Using a rat antiserum to recombinant protein, FSP95 was found only in the fibrous sheath and localized to the circumferential ribs of human sperm (Mandal et al., 1999) . Brown et al. (2003) reported that AKAP4 anchors AKAP3 and two novel spermatogenetic cells-specific proteins, Fibrous sheath interacting proteins 1 and 2 (FSIP1 and FSIP2).
Given that many AKAPs have been shown to be present in germ cells and localized to compartments related to motility where PP1g2 is also present (for instance, mitochondrial sheath or axoneme), they might be putatively involved in motility acquisition (Table II) . Among them is S-AKAP84 that localizes to the middle-piece of mouse elongating spermatids and co-localizes with mitochondria (Lin et al., 1995) . Its splice variants D-AKAP-1 (Huang et al., 1999) and AKAP121 (Feliciello et al., 1998) were also detected in mouse testis and GC2 germ cells, respectively. A PKA RII subunit binding protein, TAKAP-80, was isolated by screening a rat testis expression library (Mei et al., 1997) . The corresponding protein was detected in rat testis and in purified fibrous sheath fractions from rat epididymal sperm. The levels of protein were higher in mature compared with immature rat testis, correlating with the mRNA levels (Mei et al., 1997) . AKAP28, a 28 kDa AKAP, was detected in human testis, and was highly enriched in airway axonemes and likely to play a role in signalling mechanisms necessary for efficient modulation of ciliary beat frequency (Kultgen et al., 2002) . The distribution of WAVE1, an AKAP member of the Wiskott-Aldrich syndrome, was examined during mammalian spermatogenesis (Rawe et al., 2004) . WAVE1 localization in spermatocytes and round spermatides coincided with Golgi apparatus, whereas in elongated spermatids and testicular sperm localized to the mitochondrial sheath (Rawe et al., 2004) .
Recent data showed that inhibition of PPs with calyculin A resulted in an enhancement of the phosphorylated state at the activation loop of the PKA catalytic subunit in the mouse sperm principal and middle pieces (Goto and Harayama, 2009 PP1 modulates sperm motility co-localized in the principal piece, but PP1g2 was not present in the middle piece. It was suggested that PP1 and PP2A suppress full activation of PKA, as well as enhancement of the phosphorylated states of other flagellar proteins, in order to prevent precocious changes of flagellar movement from the progressive type to hyperactivation (Goto and Harayama, 2009 ). This suggested that PKA is dephosphorylated at the activation loop of the catalytic subunits by PP1g2 in the principal piece and by other kinds of calyculin A-sensitive PPs in the middle-piece. Nevertheless, our previous results have shown that PP1g2 is also present in the middle-piece of human sperm attributing to this phosphatase the dephosphorylation of PKA in the entire tail (Fardilha et al., 2008) . By anchoring the activity of PKA in the fibrous sheath, AKAPs can play a central role in the modulation of sperm motility. In bovine sperm, AKAP3 binds to PDE4A (phosphodiesterase 4A cAMPspecific) potentially controlling PKA activity (Bajpai et al., 2006) . Specific inhibitors of PDEs [RS23544-PDE4A5 inhibitor; (Fisch et al., 1998) ] increase the motility of the cell, and PKA-anchoring inhibitor peptides arrest sperm motility (Vijayaraghavan et al., 1997) .
Together, these findings suggest that the AKAP/PKA/PP1 complex is important for regulation of sperm motility. Sperm-specific AKAPs seem to be a very directional target for the development of male contraceptives or for infertility therapeutics (Fig. 1) .
For the complexes discussed above the common denominator is PP1g2. Thus far, we have identified 11 potential PP1g2-containing complexes all important for sperm function, and this number is likely to increase. Of marked interest is the aspect that each PP1-PIP complex discussed here has a specific sperm subcellular location (Fig. 2) . The complexes that PP1g2 forms with AKAPs represent the majority of PP1-PIP complexes here addressed, and they are distributed along the spermatozoa. Clearly, PP1g2/PIP complexes are essential regulatory components in the signalling transduction cascades involved in sperm motility acquisition during epididymal transit. Defects in any component of these signalling cascades give rise to pathological anomalies, leading to male infertility. Further work is necessary for these findings to be applied to a clinical setting.
Signal transduction therapeutics in male infertility and male contraception Cellular health and vitality are dependent on the fine equilibrium of protein phosphorylation systems. Not surprisingly, many diseases and dysfunctional states are associated with the abnormal phosphorylation of key proteins (e.g. cancer, diabetes, etc.). Thus, protein phosphorylation systems represent attractive targets for diagnostics and therapeutics. However, unlike the myriad of known protein kinases that all belong to a single gene superfamily, the PPs belong to several unrelated families. Furthermore, relatively few PP catalytic subunits exist, exhibiting broad and overlapping substrate specificities in vitro. From a medical perspective, non-selective or marginally selective phosphatase inhibitors have broad biological activity and are highly toxic to eukaryotic cells due to the inhibition of a number of critical cellular processes. Therefore, the development of non-specific inhibitors (i.e. calyculin A, microcystin and cantharidin) into therapeutic agents for systemic use seems unlikely, although the development of type and isoform-specific inhibitors is promising. Both ISIS 15534 (Zuo et al., 1998) and ISIS 14435 (Cheng et al., 2000) have been employed to specifically suppress the expression of human PP5 and PP1g1, respectively.
More interesting, however, is the data indicating that in vivo, as PPs possess exquisite specificities, both in terms of substrates and localization, the key control mechanisms must reside in the nature of the proteins to which they bind-a specific PIP. An increasing number of proteins are being identified in diverse cell types that are responsible for regulating the catalytic activity of PPs. Indeed, the diversity of such PIPs explains not only the need for few catalytic subunit types, but also makes them attractive specific targets for pharmacological intervention (McConnell and Wadzinski, 2009; Fardilha et al., 2010) . Two PP1 complexes are already under clinical trials: PP1-GADD34 to inhibit Herpes simplex virus replication (Boyce et al., 2005) and PP1-HDAC6 for cancer therapy (Chen et al., 2005) . The functional diversification of PP1 is controlled via its interaction with regulatory proteins. A major question remaining is how the regulators discriminate between virtually identical mammalian PP1 isoforms.
Since male infertility is a growing concern in industrialized nations and defects in sperm motility appear to be one of the main underlying causes, the identification and characterization of testis-and spermspecific PP1 regulatory proteins is expected to contribute towards the development of novel signal transduction therapeutic approaches to male infertility and male contraception . Globally, 128 PP1-PIPs have been described in the literature. Of these, four (Fig. 3A) are testis and sperm-specific PP1-PIP complexes and have conclusively been well documented in the literature. One hundred and seventeen PP1-PIPs have been documented in other tissues and seven complexes are common to all (Fardilha et al., 2010) . The presence in testis and sperm of specific PP1-PIP complexes makes them excellent targets for pharmacological intervention. In addition, the lower number of testis/sperm specific-PP1-PIP complexes show how important it is to determine the identity and define the properties of novel protein regulators of human testis/sperm PP1g. Theoretically, we anticipate a minimum of 11 complexes (Fig. 2 ) but these must be confirmed.
Exhaustive yeast two-hybrid screens of human testis libraries using the baits PP1g1, PP1g2 and PP1g2 C-terminal have revealed more than 70 new interactions, apart from previously known 'bona fide' PP1 interactors such as Nek2 and NIPP1 . Several PP1-PIP complexes have already been identified (Fardilha, 2003; Fardilha et al., 2004; Browne et al., 2007; Wu et al., 2007) with the objective of pharmacologically modulating their activities. Moreover, the identification of testis/sperm specific variants of PIPs may lead to excellent candidates for the development of new drugs to control testis/sperm specific processes such as motility, without affecting other key signal transduction pathways in other tissues (Fig. 3B) .
Conclusions
The accessibility of spermatozoa and the recent proteomics advances have resulted in the identification of the proteins that make up sperm cells (Oliva et al., 2008) . Also, the development of genetic systems, such as the yeast two-hybrid system (Fields and Song, 1989) , allowed the detection of novel protein-protein interactions. These interactions are the basis of sperm function since these cells are basically devoid of transcription and translation and are ideal targets for therapeutical intervention. Furthermore, worldwide, the market for oral contraceptives is worth billions of euros and the demand for a non-hormonal oral male contraceptive is likely to have a phenomenal impact. The protein complexes, PP1g2/I2-L/GSK-3, PP1g2/sds22, PP1g2/I3, sds22/PP1/I3, PP1g2/14-3-3 and PP1g2/ AKAP/PKA, here described are attractive to regulate sperm motility and consequently inducing or inhibiting sperm function. Thus, given the growing concerns with increasing infertility in our modern society, PP1-based signal transduction must be further pursued with respect to its diagnostic and therapeutic potential. The diagram was based in PP1-PIP complexes whose interaction is well documented in literature (Fardilha et al., 2010) . (B) Signal transduction therapeutics for sperm-specific processes based on the targeting of sperm-specific PP1-PIP holoenzymes. A drug targeting a specific PP1-PIP (for instance, in testis or sperm) would not influence another PP1 complex in a different tissue. PIP(T/S), PP1 interacting protein in testis/sperm; PIP (OT), PP1 interacting protein in other tissues; PP1, protein phosphatase 1.
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